We are pioneering approaches to exploit Dark Antigen™ targets with a range of immunotherapeutic modalities, such as bispecific T-cell engagers and adoptive cell therapies.
Generating products to improve outcomes for cancer patients
Our proprietary database of tumor-specific antigens is the foundation for a diverse range of product candidates that can be advanced into clinical development internally or through partnerships. Our primary focus is to improve outcomes for broad populations of cancer patients by developing TCR-directed immunotherapies against shared targets that have high prevalence and are homogenously expressed within tumors.
Multiple Dark Antigens can be combined to create off-the-shelf therapeutic cancer vaccines, which is a key objective of our collaboration with Boehringer Ingelheim.